"The study adds to growing evidence that dupilumab, while highly effective for managing atopic dermatitis, may also be linked ...

Dupilumab may provide a nonsteroidal option for managing cancer therapy-related skin toxicities, according to a study.

CSPC Pharmaceutical Group ( ($HK:1093) ) has issued an update. CSPC Pharmaceutical Group has announced that its Dupilumab Injection, a biosimilar ...

Anabelle Terry, a slender, self-possessed 13-year-old, has heard the peanut butter story her entire life. A visit to an ...

For nearly a decade, 71-year-old Ho Thian Kong struggled with the effects of chronic rhinosinusitis with nasal polyps, a ...

For severe chronic rhinosinusitis with nasal polyps, novel stapokibart reduced symptoms and polyp size atop treatment with a ...

With multiple novel therapies expected and the treatment paradigm shifting toward earlier intervention, the market will grow ...

Identifying specific biomarkers and clinical characteristics is crucial for predicting a patient's response to both existing and emerging treatments for chronic spontaneous urticaria, thereby moving ...

Among adults with severe asthma, those with healthy weight, overweight, obesity and severe obesity each had improvements in ...

Initiated Phase 2 Seabreeze STAT asthma and COPD studies evaluating rademikibart as an adjunct treatment for acute exacerbations – – Presented positive data at ATS 2025 and EAACI 2025 supporting the ...

The first of those phase 3 trials has now reported preliminary results, with IL-4 and IL-3 inhibitor Dupixent (dupilumab) hitting the mark across the study’s primary and secondary endpoints ...

Sanofi is already a major player in the ASD market with its big-selling IL-4 and IL-13 inhibitor Dupixent (dupilumab), and the company has previously highlighted amlitelimab as one of a dozen ...